25 April 2012 - KYTHERA Biopharmaceuticals Inc (KYTHERA) on Wednesday announced with Bayer the successful completion of two European Phase III clinical trials with ATX-101, an injectable drug designed for the reduction of unwanted fat under the chin.

In a top-line analysis of the trial data...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up